Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

April 22, 2009

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies. One study confirms the anti-tumor effects and immune stimulating ability of a fully human anti-PS antibody and the other demonstrates the ability of a second fully human anti-PS antibody to stimulate development of a critical component of the adaptive immune system.

These human PS-targeting antibodies, which are currently being evaluated for both anti-cancer and anti-viral applications, increase the number of product candidates in Peregrine's anti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in Phase II clinical trials in advanced breast and lung cancers.




"These preclinical studies further elucidate the unique immunomodulatory mechanisms contributing to the observed anti-tumor activity of anti-PS antibodies in preclinical and clinical studies," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center in Dallas, a scientific advisor to Peregrine and co-author of one of the AACR presentations. "These presentations provide additional insight into the mechanisms that act to selectively destroy the blood vessels supporting tumor growth and spread and also to reverse the ability of tumors to suppress the body's natural immune response, resulting in the mobilization of important inflammatory and other anti-tumor components of the immune system. Together, the studies provide compelling evidence suggesting that PS-targeting antibodies facilitate an important cytokine shift in the tumor environment that subsequently encourages multiple types of immune system cells to mount anti-tumor responses."

In a presentation1 on Monday, a series of preclinical studies by a team of scientists from Peregrine Pharmaceuticals and Affitech A/S used a fully human anti-PS antibody, PGN635, to confirm previous observations that in vitro, anti-PS antibodies stimulate the tumor microenvironment to recruit monocytes and other immune cells to the tumor with resulting anti-tumor effects, most likely via cell-mediated mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). Their data further define the role of anti-PS antibodies in mediating tumor cell cytotoxicity and the tumor microenvironment, showing that the anti-PS antibody induced a sequential release of cytokines and beta-chemokines and stimulated enhanced macrophage recruitment to tumors. Furthermore, the researchers showed that in vitro, PGN635 induced antibody-dependent death of endothelial cells, the same cell type found in the tumor vasculature, a key target of anti-PS cancer therapy. The studies also demonstrated the anti-tumor potential of PGN635 in vitro and in a number of animal cancer models.

"Data from our experiments has helped to clarify details regarding the mechanisms responsible for the anti-tumor results observed with Peregrine's PS-targeting antibodies," said Dr. Monica Friedrich, a Peregrine research scientist and lead author of the study. "In data presented at this conference last year, we demonstrated that our fully human antibody PGN635 localizes to tumors and causes an increase in several inflammatory cytokines while decreasing an important anti-inflammatory cytokine. The new data we present confirms that PGN635 also triggers immune cells to produce other chemokines and cytokines that have the potential to alter the suppressed immune environment commonly found in tumors, attracting additional immune cells and stimulating more aggressive anti-tumor responses. We believe this upregulation of the immune response contributes to the encouraging anti-tumor effects demonstrated by PGN635 and other anti-PS antibodies."

A second study2 presented on Monday by researchers from UT Southwestern Medical Center and Affitech demonstrated the ability of Peregrine's fully human PS-targeting antibody PGN632 to promote the maturation of dendritic cells, important antigen-presenting cells of the immune system. In the in vitro studies, immature dendritic cells cultured in the presence of PGN632 exhibited a significant increase in the production of inflammatory cytokines and chemokines. PGN632 also induced an increase in the expression of cell-surface molecules that are indicative of mature dendritic cells and that assist in antigen presentation functions, as well as in stimulating T-cell proliferation.

Dr. Xianming Huang, assistant professor of pharmacology at UT Southwestern Medical Center and lead author of the study, noted, "Dendritic cells are the professional antigen-presenting cells of the immune system and they play a crucial role in initiating adaptive immune responses. Dendritic cells must be mature, or activated, to be effective, yet tumors and other pathogens such as viruses often possess the ability to undermine this maturation, thereby suppressing the immune response. The results presented today suggest that by blocking exposed PS, anti-PS antibodies have the potential to promote dendritic cell maturation in the body and thereby stimulate a more effective immune response."

The fully human PS-targeting antibodies in these studies were developed through Peregrine's collaboration with Affitech A/S. The study by Dr. Huang, et al. was partly supported by the Gillson Longenbaugh and Meredith D. Chesler Foundations.

Peregrine president and CEO Steven King commented, "It is noteworthy that these studies were primarily conducted using our new fully human antibodies, which could serve as the basis for the next generation of anti-PS therapies. Our PS-targeting antibody platform now includes several promising antibodies in preclinical evaluation that vary in their binding profile and in their specific immunomodulatory activity. The unique functional characteristics of these different antibodies open the door to new product candidates and extended applications for our anti-PS technology. We are more encouraged than ever that our anti-PS platform has very broad potential, and we look forward to further development of our growing preclinical pipeline of PS-targeting candidates both through internal efforts and collaborations with partners."

About Peregrine's Clinical Stage Anti-PS Antibody Bavituximab

Peregrine's clinical stage PS-targeting antibody bavituximab binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

BioCom Partners



Related Antibodies Current Events and Antibodies News Articles Antibodies Current Events and Antibodies News RSS Antibodies Current Events and Antibodies News RSS
New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.

PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.

Study reveals a 'missing link' in immune response to disease
The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

Breakthrough in industrial-scale nanotube processing
Rice University scientists today unveiled a method for the industrial-scale processing of pure carbon-nanotube fibers that could lead to revolutionary advances in materials science, power distribution and nanoelectronics.

Breakthrough in fight against Hendra virus
There has been a breakthrough in the fight against the deadly Hendra virus following the development of a treatment which shows great potential to save the lives of people who become infected with the virus.

USU scientists report major advance in human antibody therapy against deadly Nipah virus
A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease
Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

Exploring the final frontier: Disease proposed as major barrier to Mars and beyond
New research published in the Journal of Leukocyte Biology suggests that prolific virulence and growth of bacteria, coupled with reduced production of antibodies could limit future space travel.
More Antibodies Current Events and Antibodies News Articles
Antibodies (Two-Disc Special Edition)

Antibodies (Two-Disc Special Edition)
Starring: Norman Reedus, Christian von Aster, André Hennicke, Waltraud Witte, Konstantin Graudus
Directed By: Christian Alvart

Studio: Mpi Home Video Release Date: 08/28/2007 Run time: 128 minutes

Antibodies: A Laboratory Manual

Antibodies: A Laboratory Manual
by Ed Harlow (Author), David Lane (Author)

Introduction to immunochemistry for molecular biologists and other nonspecialists. Spiral.

Making and Using Antibodies: A Practical Handbook

Making and Using Antibodies: A Practical Handbook
by Gary C. Howard (Editor), Matthew R. Kaser (Editor)

Antibodies are an indispensable tool in the study of biology and medicine. Making and Using Antibodies: A Practical Handbook presents techniques in a single, comprehensive source for the production and use of antibodies. It enables researchers to immediately access lab-tested, proven protocols.

Written and edited by an elite team of scientists, who have developed and refined many of the methods, this book covers-
Commercially available adjuvants designed for the production of antisera in the research setting
Methods for the production, purification, and characterization of antibodies
Practical guidance to researchers needing to modify antibodies
Basic techniques including enzyme-linked immunosorbent assay (ELISA), Western blotting, immunohistochemistry, and flow...

Chronicle of an Escape

Chronicle of an Escape
Starring: Rodrigo De la Serna, Pablo Echarri, Nazareno Casero, Lautaro Delgado, Matías Marmorato
Directed By: Adrián Caetano
Also With: Adrián Caetano (Writer), Alejandra Dixon (Producer), Hugo Sigman (Producer), Paula Zyngierman (Producer), Claudio Tamburrini (Writer), Esteban Student (Writer), Julian Loyola (Writer)

A soccer player is suddenly ripped from the field and finds himself on the floor of a horrific detention center. What follows is a living hell of interrogations and relentless mental and physical abuse. Alongside other young detainees, he battles to survive while awaiting his fate to be decided. With execution looking certain, he and three other prisoners will risk their lives and make a desperate and extraordinarily brave move for freedom.

Punish Me

Punish Me
Starring: Ullman; Kroymann; Vollenklee
Directed By: Angelina Maccarone

Jan is a 16-year-old juvenile delinquent placed under the watchful eye of Elsa Seifert, a stern, driven, and uncompromising 49-year-old probation officer. Elsa cares for her charges, but tolerates no stepping out of line. But now, as she approaches 50, cracks begin to appear in Elsa's professionalism. As her grown daughter prepares to leave home, and her marriage becomes more and more strained, Elsa longs for the intensity of experiencing something outside of her routine, something outside the norm.

Young, obsessed, Jan eagerly fills this void, offering to sexually subjugate himself to her. And Elsa enters willingly into this risky venture, desiring the verboten, but knowing it cannot end well.

Winner of the Golden Leopard prize at the 2006 Locarno Film Festival, PUNISH ME...

Monoclonal Antibodies in Biotechnology: Theoretical and Practical Aspects (Cambridge Studies in Biotechnology)

Monoclonal Antibodies in Biotechnology: Theoretical and Practical Aspects (Cambridge Studies in Biotechnology)
by Kenneth C. McCullough (Author), Raymond E. Spier (Author)

This volume provides a complete description of the principles, methodologies and applications of monoclonal antibodies, one of the most exciting developments to occur in biotechnology in recent years, and a powerful technology for modern industry and science. The immune system and the role of the antibody are described and full details are given on how the hybridomas are formed, isolated, and maintained in culture such that the required antibody can be produced to a high degree of purity. The authors describe all the methodologies involved, all the reagents and solutions and all the assay conditions required for their production. The material is presented to enable research and development managers to make choices as to which are the most suitable techniques for their requirements. The...

Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology)

Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology)
by Maher Albitar (Editor)

Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion protein, and the use of antibodies and flow cytometry in the quantification of cell signaling proteins. Specific chapters describe how antibodies are used for the diagnosis and classification of hematologic diseases. Subsequent chapters examine the advantages and most recent advances of using bead-based immunoassays, including the ability of bead-based technology to multiplex and analyze several...

  Human Antibodies
by Ios Press



  Antibodies



Trip on Cocaine

Trip on Cocaine
Strange Antibody (Primary Contributor)



© 2009 BrightSurf.com